Trials / Completed
CompletedNCT05260437
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
A Phase 1, Open-label, Safety, Reactogenicity, and Immunogenicity Trial of the CV2CoV mRNA Vaccine Against SARS CoV 2 in Seropositive Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CV2CoV (2 µg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV2CoV (4 µg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV2CoV (8 µg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV2CoV (12 µg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV2CoV (16 µg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV2CoV (20 µg) | Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it. |
Timeline
- Start date
- 2022-03-24
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
- First posted
- 2022-03-02
- Last updated
- 2024-08-12
- Results posted
- 2024-08-12
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05260437. Inclusion in this directory is not an endorsement.